26-Mar-2026
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences
TipRanks (Tue, 24-Mar 6:44 AM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 24-Mar 6:00 AM ET)
Zymeworks Highlights Promising Zanidatamab Data Across HER2+ Cancers at Upcoming AACR Meeting
Market Chameleon (Wed, 18-Mar 3:53 AM ET)
Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting
Globe Newswire (Wed, 18-Mar 7:46 AM ET)
Globe Newswire (Tue, 17-Mar 5:11 PM ET)
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
Globe Newswire (Mon, 2-Mar 6:10 AM ET)
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Globe Newswire (Mon, 2-Mar 6:01 AM ET)
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Mon, 2-Mar 6:00 AM ET)
Globe Newswire (Thu, 12-Feb 6:00 AM ET)
Globe Newswire (Mon, 12-Jan 6:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of March 26, 2026, ZYME stock price climbed to $24.69 with 358,498 million shares trading.
ZYME has a beta of 0.64, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.04 to the broad based SPY ETF.
ZYME has a market cap of $1.83 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $3 million in Revenue and -$.55 earnings per share. This fell short of revenue expectation by $-18 million and missed earnings estimates by -$.22.
In the last 3 years, ZYME traded as high as $28.49 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a price return of +92.9% while the SPY ETF gained +13.4%. However, in the short term, ZYME had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.1% vs -6.3% return in SPY. But in the last 2 weeks, ZYME shares have fared better than the market returning -1.8% compared to SPY -4.4%.
ZYME support price is $23.42 and resistance is $25.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.